ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...

Primary Biliary Cholangitis Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Ipsen, Zydus, COUR, Calliditas, CymaBay, Mirum, Intercept, Escient, GlaxoSmithKline New York, USA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Primary Biliary Cholangitis Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Ipsen, Zydus, COUR,...

ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...

Global Primary Biliary Cholangitis Treatment Market to surpass US$ 10,820.8 million by 2026 - Coherent Market Insights SEATTLE, March 19, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global Primary Biliary Cholangitis Treatment Market was valued at US$ 526.4 million in 2017, and is projected...

CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC) Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacyLarge...